Market research
AVDL Avadel Pharmaceuticals PLC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- 0.0
- Analyst target
- 20.7143
- Dividend yield
- Not available
- Beta
- 1.63
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- IE00BDGMC594
- Market cap
- 2B
- P/E ratio
- 0.0
- Analyst target
- 20.7143
- Dividend yield
- Not available
- Beta
- 1.63
About
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AVDL discussion.
5 years, 4 months ago
Avadel Pharmaceuticals plc is currently in a long term downtrend where the price is trading 4.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.9.
Avadel Pharmaceuticals plc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 311.8% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 131.7% to $-19M since the same quarter in the previous year.
Based on the above factors, Avadel Pharmaceuticals plc gets an overall score of 1/5.